Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
Becton Dickinson & Co executive Michael David Garrison reported an open-market sale of company stock. On June 10, 2026, he sold 1,100 shares of Common Stock at an average price of $151.48 per share. After this transaction, he directly holds 14,272 shares. A footnote explains that his direct holdings reflect prior adjustments tied to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the number of shares underlying previously reported, unvested time-vested restricted stock units.
Becton Dickinson notified the New York Stock Exchange of the removal of its 1.208% Notes due 2026 from listing and registration under Section 12(b) of the Exchange Act. The Exchange certified compliance with rules under 17 CFR 240.12d2-2 and the issuer certified its compliance with voluntary withdrawal requirements.
Becton Dickinson & Co. Chairman, CEO and President Thomas E. Polen Jr. reported several transactions in company common stock. He sold 2,764 shares in an open-market sale at a weighted average price of $146.35 per share, with actual prices ranging from $145.21 to $147.49. He also disposed of 17,445 shares to the issuer at $146.15 per share and exercised stock appreciation rights covering 20,209 shares at an exercise price of $126.16 per share, receiving the underlying common stock. After these moves, he continues to hold over 100,000 shares directly, indicating that the transactions represent a partial, not complete, change in his equity position.
Menziuso Peter reported acquisition or exercise transactions in this Form 4 filing.
Becton Dickinson & Co. executive Peter Menziuso, EVP and President, BDI, received a grant of 14,258 shares of Common Stock on June 1, 2026. The award is in the form of restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan and carries no purchase price.
Following this compensation-related grant, Menziuso directly holds 14,258 shares of Becton Dickinson common stock. This is an equity incentive award rather than an open-market share purchase or sale.
Becton Dickinson & Co executive Peter Menziuso, EVP and President of BDI, filed an initial Form 3 reporting his beneficial ownership status in the company’s common stock. The filing shows he held no shares of common stock directly as of the reported date.
Becton, Dickinson and Company resumed U.S. shipments of its ChloraPrep™ product after a voluntary ship hold while it conducted additional final release testing. The company had previously placed both ChloraPrep™ and PurPrep™ on ship hold in the U.S. on May 6, 2026.
The ship hold was implemented in response to an FDA Warning Letter for BD’s El Paso manufacturing facility and to allow additional release testing. BD states that all additional final release testing to date has been acceptable and that there have been no patient safety signals.
The company refers investors to its latest Annual Report on Form 10-K, its Form 10-Q for the period ended March 31, 2026, and other SEC filings for a detailed discussion of the El Paso Warning Letter, related risks, and broader forward-looking risk factors.
Becton Dickinson & Co Executive Vice President and Chief Revenue Officer Michael Feld sold 75 shares of Common Stock in an open-market transaction at $147.35 per share. After this sale, he directly holds 21,084 shares of the company.
Form 144 notice of proposed sale and recent Rule 10b5-1 sales. The filing lists 75 Restricted Stock Units of Common Stock stated as securities to be sold, with an associated date of 08/20/2025. The excerpt also records two recent 10b5-1 sales by Michael Feld: 74 shares on 04/27/2026 for $11,243.56 and 75 shares on 03/26/2026 for $11,762.25. The broker/filer shown is Morgan Stanley Smith Barney LLC and the security is listed on the NYSE.